Glucocorticoid resistance in chronic lymphocytic leukaemia is associated with a failure of upregulated Bim/Bcl-2 complexes to activate Bax and Bak
Open Access
- 16 August 2012
- journal article
- research article
- Published by Springer Nature in Cell Death & Disease
- Vol. 3 (8) , e372
Abstract
Glucocorticoids (GCs) represent an important component of modern treatment regimens for fludarabine-refractory or TP53-defective chronic lymphocytic leukemia (CLL). However, GC therapy is not effective in all patients. The molecular mechanisms responsible for GC-induced apoptosis and resistance were therefore investigated in primary malignant cells obtained from a cohort of 46 patients with CLL. Dexamethasone-induced apoptosis was unaffected by p53 dysfunction and more pronounced in cases with unmutated IGHV genes. Cross-resistance was observed between dexamethasone and other GCs but not fludarabine, indicating non-identical resistance mechanisms. GC treatment resulted in the upregulation of Bim mRNA and protein, but to comparable levels in both GC-resistant and sensitive cells. Pre-incubation with Bim siRNAs reduced GC-induced upregulation of Bim protein and conferred resistance to GC-induced apoptosis in previously GC-sensitive cells. GC-induced upregulation of Bim was associated with the activation of Bax and Bak in GC-sensitive but not -resistant CLL samples. Co-immunoprecipitation experiments showed that Bim does not interact directly with Bax or Bak, but is almost exclusively bound to Bcl-2 regardless of GC treatment. Taken together, these findings suggest that the GC-induced killing of CLL cells results from the indirect activation of Bax and Bak by upregulated Bim/Bcl-2 complexes, and that GC resistance results from the failure of such activation to occur.Keywords
This publication has 41 references indexed in Scilit:
- Alemtuzumab in Combination With Methylprednisolone Is a Highly Effective Induction Regimen for Patients With Chronic Lymphocytic Leukemia and Deletion of TP53: Final Results of the National Cancer Research Institute CLL206 TrialJournal of Clinical Oncology, 2012
- Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibitionBlood, 2010
- From pathogenesis to treatment of chronic lymphocytic leukaemiaNature Reviews Cancer, 2009
- Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemiaLeukemia, 2009
- Drug cross‐resistance and therapy‐induced resistance in chronic lymphocytic leukaemia by an enhanced method of individualised tumour response testingBritish Journal of Haematology, 2009
- Molecular mechanisms regulating glucocorticoid sensitivity and resistanceMolecular and Cellular Endocrinology, 2009
- The BCL-2 protein family: opposing activities that mediate cell deathNature Reviews Molecular Cell Biology, 2008
- Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737Journal of Clinical Investigation, 2007
- Activation of Bak, Bax, and BH3-only Proteins in the Apoptotic Response to DoxorubicinJournal of Biological Chemistry, 2002
- Imbalanced Expression of the Glucocorticoid Receptor Isoforms in Cultured Lymphocytes from a Patient with Systemic Glucocorticoid Resistance and Chronic Lymphocytic LeukemiaBiochemical and Biophysical Research Communications, 1999